“We believe this an appropriate strategic response to the current capital market environment which values several key names in the space—most with novel, differentiated therapies effective against the rising threat of multi-drug resistant (MDR) infections—at what we view as surprisingly low levels, especially given that several have now eliminated clinical risk. To wit, Nabriva’s market value has been steadily declining from a $300M market cap about a year ago, before positive pivotal data from LEAP 1 or LEAP 2. As a result of this acquisition, Nabriva now has two novel, first-in-class drugs: IV and oral lefamulin for CABP; and CONTEPO (IV fosfomycin), a broad spectrum, epoxide class drug for cUTI. In Europe, IV fosfomycin is generic with a well- established efficacy and safety profile from over 45 years of clinical use.”
According to TipRanks.com, Arce is a 5-star analyst with an average return of 25.1% and a 43.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Aurinia Pharmaceuticals.
Nabriva has an analyst consensus of Strong Buy, with a price target consensus of $18, representing a 445.5% upside. In a report released yesterday, Cantor Fitzgerald also assigned a Buy rating to the stock with a $16 price target.
The company has a one-year high of $14.10 and a one-year low of $3.26. Currently, Nabriva has an average volume of 490.5K.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NBRV in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nabriva Therapeutics Plc is a clinical stage biopharmaceutical company, which engages in the research and development of novel antibiotics to treat serious infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic available for systemic administration in humans.